AZN · story · 14 November
AstraZeneca · 7 headlines from 7 outlets, on 14 November 2026.
The CHMP recommended approval of AstraZeneca's baxdrostat, branded Baxfendy, for uncontrolled hypertension.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Yahoo Finance is the largest at 10.0, ahead of Arab News (9.2). Tech Times is the smallest at 5.8.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Yahoo Finance | 10.0 |
| Arab News | 9.2 |
| London South East | 9.2 |
| Mezha.net | 9.2 |
| Securities.io | 9.2 |
| StreetInsider | 9.2 |
| Tech Times | 5.8 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Yahoo Finance | 1 | +10.0 |
| Arab News | 1 | +9.2 |
| London South East | 1 | +9.2 |
| Mezha.net | 1 | +9.2 |
| Securities.io | 1 | +9.2 |
| StreetInsider | 1 | +9.2 |
| Tech Times | 1 | +5.8 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | European committee recommends approval of new blood pressure drug. |
| +9.2 | EU panel supports hypertension drug. |
| +9.2 | Company says hypertension drug recommended for European approval. |
| +9.2 | EU committee supports marketing authorisation for baxdrostat. |
| +9.2 | Committee backs drug for uncontrolled high blood pressure. |
| +9.2 | Hypertension drug recommended for European approval. |
| +5.8 | EU backing for hypertension drug, with US pricing pressure noted. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.